Glenmark Pharmaceuticals has launched RYALTRIS Nasal Spray in Brazil to treat moderate to severe allergic rhinitis symptoms. The launch follows regulatory approval from Agência Nacional de Vigilância Sanitária (ANVISA) earlier this year.

The product targets adults and adolescents aged 12 years and older. It marks a significant expansion of Glenmark’s innovative respiratory portfolio in Latin America.

Product Details

RYALTRIS is the first olopatadine-containing intranasal combination therapy available in Brazil. The spray combines two active ingredients:

• Olopatadine hydrochloride (antihistamine)
• Mometasone furoate (corticosteroid)

This dual-action formulation offers a differentiated treatment option for patients. Allergic rhinitis affects an estimated 20–30% of the Brazilian population, representing nearly 40–60 million people.

Global Footprint

RYALTRIS is Glenmark’s first globally commercialized branded innovative product. It has received approval in 57 markets worldwide. Key regions include:

• United States
• European Union
• United Kingdom
• Australia
• South Korea
• Russia
• China

Marco Cerato, Executive Vice President & Global Head – Innovative Business at Glenmark Pharmaceuticals, stated that the launch reflects the company’s commitment to science-led innovation. He noted that Brazil provides a strategic opportunity as the largest healthcare market in Latin America.

What the Numbers Show

The launch of RYALTRIS in Brazil adds to a portfolio already approved in 57 markets. This geographic expansion highlights the scalability of Glenmark’s differentiated respiratory therapies across diverse regulatory environments.

Glenmark Pharmaceuticals has launched Calcium Gluconate Injection USP in the United States, targeting a significant segment of the hospital injectables market. The launch includes single-dose vials and pharmacy bulk packages in three strength configurations.

The new product is bioequivalent and therapeutically equivalent to the reference listed drug manufactured by Fresenius Kabi USA, LLC. Glenmark’s offering covers 1,000 mg/10 mL, 5,000 mg/50 mL, and 10,000 mg/100 mL formulations.

Market Opportunity

According to IQVIA sales data for the 12-month period ending June 2026, the relevant market for these injection strengths achieved annual sales of approximately $69.9 million. This figure encompasses both brand products and all available therapeutic equivalents.

Strategic Expansion

Marc Kikuchi, President & Business Head for North America, stated that the launch strengthens Glenmark’s U.S. injectables business. He noted the move expands the hospital portfolio and supports supply resilience across the U.S. healthcare system.

What the Numbers Show

The entry into a nearly $70 million market with a therapeutically equivalent generic suggests a direct competitive challenge to Fresenius Kabi. By offering multiple package sizes including pharmacy bulk packages, Glenmark aims to capture institutional demand where volume pricing often drives procurement decisions.